Antibody-Drug Conjugates Targeting Lipopolysaccharides for Bacterial Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of antibiotic-resistant bacterial strains complicates the treatment of infections, leading to increased disability and death, and existing antibiotic use contributes to resistance, necessitating new approaches for treating, preventing, and diagnosing bacterial infections.
Innovation Solution
Development of antibody molecule-drug conjugates (ADCs) that bind to Gram-negative bacteria by targeting lipopolysaccharides, comprising antimicrobial peptides covalently coupled to anti-LPS antibodies, improving binding affinity and inhibitory properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat bacterial infections, then infections can be treated, but antibiotic-resistant bacterial strains emerge
Solution Approach 1:
The patent creates an antibody-drug conjugate by covalently coupling antimicrobial peptides to anti-LPS antibodies. This composite structure combines the specific binding capability of antibodies with the antimicrobial activity of peptides, creating a targeted therapy that delivers the antimicrobial agent directly to Gram-negative bacteria while reducing systemic exposure and resistance development
Solution Approach 2:
The anti-LPS antibody serves as an intermediary that specifically recognizes and binds to lipopolysaccharides on the surface of Gram-negative bacteria. This intermediary function enables selective delivery of the antimicrobial peptide to the target bacteria, improving treatment effectiveness while minimizing off-target effects that contribute to resistance
2Reliability
If antimicrobial peptides are used alone, then they can inhibit bacteria, but they have limited stability and binding affinity
Solution Approach 1:
The patent merges the antimicrobial peptide with the anti-LPS antibody through covalent coupling to form an antibody-drug conjugate. This combination preserves the antimicrobial activity of the peptide while the antibody portion provides enhanced stability, prolonged circulation time, and targeted delivery to bacteria
Solution Approach 2:
By conjugating the peptide to the antibody, the patent fundamentally changes the pharmacokinetic parameters of the antimicrobial agent. The conjugate exhibits improved stability, altered distribution patterns, and enhanced binding affinity through the antibody's high-affinity interaction with LPS, while maintaining the peptide's bactericidal activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ADCs demonstrate enhanced ability to inhibit and reduce the viability of Gram-negative bacteria, potentially offering a more effective treatment option with reduced resistance probability and improved stability compared to standalone antimicrobial peptides.
Implementation Method 1
antibody molecule-drug conjugates (ADC) that bind to Gram-negative bacteria, e.g., lipopolysaccharides (LPS) on the outer membrane of Gram-negative bacteria
Implementation Method 2
comprise an antimicrobial peptide site-specifically coupled (e.g., conjugated) to an anti-LPS antibody molecule
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.